# TAU N279K Research Report

**Protein:** TAU N279K
**Variant:** N279K
**UniProt ID:** P10636
**Disease Association:** Alzheimer's disease
**Report Generated:** 2026-05-30 20:55 UTC
**AlphaFold Confidence (pLDDT):** 54.2%
**Structure Folded:** 2026-05-12

---

## Structure Summary

Tau is a brain protein that stabilizes the cellular scaffolding (microtubules) in neurons, but in Alzheimer's disease it forms toxic tangles that spread through the brain and correlate with cognitive decline. The N279K variant, which replaces a neutral amino acid with a positively charged one in tau's microtubule-binding region, is classified as pathogenic by expert panels and has never been observed in the general population, suggesting it directly causes disease. Structural modeling of this variant shows extremely low confidence (average 54.2 out of 100), reflecting tau's naturally disordered structure, which makes it prone to the abnormal folding and aggregation seen in Alzheimer's disease.

---

The tau protein (MAPT gene) normally binds to and stabilizes microtubules, the transport highways inside neurons that are essential for moving cargo throughout these long cells. In Alzheimer's disease and related dementias, tau becomes hyperphosphorylated (decorated with phosphate groups), detaches from microtubules, and aggregates into neurofibrillary tangles that spread systematically through the brain [1]. The density and distribution of these tangles correlates strongly with cognitive decline, making tau a central therapeutic target [1][4].

The N279K variant replaces asparagine (a polar, neutral amino acid) with lysine (a positively charged amino acid) at position 279, located within tau's microtubule-binding repeat region. This variant is classified as pathogenic by multiple expert submitters in ClinVar based on established criteria, and critically, it has never been observed in gnomAD, a database cataloging genetic variation in over 140,000 individuals from diverse populations. The complete absence in healthy populations combined with pathogenic classification strongly indicates this variant directly causes disease rather than being a benign polymorphism. Disease-causing MAPT variants are well-documented to cause frontotemporal dementia and parkinsonism, with molecular mechanisms including altered tau phosphorylation, increased aggregation propensity, and disrupted microtubule binding [2][5].

Structural modeling using AlphaFold2 predicts N279K tau with an average confidence score (pLDDT) of 54.2, which is extremely low by structural biology standards. However, this low confidence is expected and biologically meaningful: tau is an intrinsically disordered protein, meaning it lacks a stable three-dimensional structure in its normal, soluble state. This disordered nature is precisely what allows tau to flexibly bind microtubules and respond to regulatory phosphorylation, but it also makes tau vulnerable to pathological misfolding. When tau becomes hyperphosphorylated or carries disease-causing mutations, it can transition from this disordered state into structured, beta-sheet-rich aggregates that form the core of neurofibrillary tangles [3][5]. The N279K substitution, by introducing an additional positive charge in a region critical for microtubule binding, likely disrupts normal tau-microtubule interactions and may promote pathological conformational changes.

Recent research has identified multiple pathological tau species beyond full-length protein, including N-terminal truncated forms and acetylated variants that show functional relevance in Alzheimer's disease [3][4]. Studies using patient-derived neurons carrying MAPT mutations reveal early changes in axon development and altered tau phosphorylation patterns, suggesting disease-causing variants disrupt tau function during neuronal maturation long before tangle formation [2]. Advanced cellular models, including cerebral organoids with CRISPR-edited tau phosphorylation sites, demonstrate that both neuronal and astrocytic tau contribute to soluble phospho-tau biomarkers now used clinically to track Alzheimer's progression [5].

The pathogenic classification, population absence, and location within the microtubule-binding domain collectively indicate N279K represents a high-confidence disease-causing variant. While the low structural confidence score reflects tau's intrinsic disorder rather than modeling failure, it underscores the challenge of predicting how specific mutations alter the conformational landscape of disordered proteins. Future experimental studies using patient-derived neurons or engineered organoid models would be valuable to directly measure how N279K affects tau phosphorylation, microtubule binding, aggregation kinetics, and neuronal function [2][5][6].

## Works Cited

[1] Robinson et al. (2026). Idiotypic-susceptible Alzheimer's disease: a clinically relevant, neurofibrillary tangle subtype. Acta neuropathologica. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42069798/)

[2] Mohl et al. (2026). Multi-omic phenotyping of MAPT V337M neurons reveals early changes in axonogenesis and tau phosphorylation. NPJ dementia. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42046563/)

[3] Guedjdal et al. (2026). N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer's disease. Translational neurodegeneration. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42046086/)

[4] Honey et al. (2026). An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration. Nature medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41986736/)

[5] Zhang et al. (2026). Engineered Alzheimer Organoids Validate the Link Between Intracellular and Soluble p-Tau Biomarkers and Highlight the Contribution of Astrocytic Tau. Neuroscience bulletin. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41964788/)

[6] Chen et al. (2026). Study on the improvement effect and mechanism of resveratrol on cognitive impairment in tau mutant adenovirus-induced alzheimer's disease model mice. Psychopharmacology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42089987/)


## Similar Research

**Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.**
Ashton et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/)

**Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.**
Sogorb-Esteve et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/)

**Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?**
Ciechanover et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/)

**Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.**
Inigo-Catalina et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/)

**Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.**
Gerlando et al. (2026)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/)

---

## Clinical Data

### ClinVar
- **Classification:** Pathogenic
- **Review Status:** criteria provided, multiple submitters
- **Last Evaluated:** 2026-01-01

### gnomAD

Not found in gnomAD.

---

## Open Targets Disease Associations

| Disease | Score | Data Sources |
|---------|-------|--------------|
| Pick disease | 0.760 | literature, animal_model, genetic_association, genetic_literature |
| frontotemporal dementia | 0.736 | literature, genetic_association |
| supranuclear palsy, progressive, 1 | 0.735 | literature, genetic_association, genetic_literature |
| Atypical progressive supranuclear palsy | 0.723 | animal_model, genetic_association, genetic_literature |
| Progressive supranuclear palsy - parkinsonism | 0.722 | literature, genetic_association, genetic_literature |
| Classical progressive supranuclear palsy | 0.717 | literature, genetic_association, clinical, genetic_literature |
| progressive supranuclear palsy | 0.708 | literature, genetic_association, genetic_literature, clinical |
| progressive supranuclear palsy-parkinsonism syndrome | 0.655 | literature, genetic_association, genetic_literature |
| semantic dementia | 0.651 | literature, animal_model, genetic_association, genetic_literature |
| late-onset Parkinson disease | 0.632 | literature, genetic_association, genetic_literature |

*...and 1172 more associations*

---

## AI Research Brief

# Research Brief: TAU N279K Variant

## Pathogenic Mechanisms

The TAU N279K mutation represents a pathogenic variant that fundamentally disrupts tau protein function through multiple converging mechanisms. Located within the microtubule-binding domain, this asparagine-to-lysine substitution at position 279 significantly impairs tau's ability to bind and stabilize microtubules, a core function essential for maintaining neuronal cytoskeletal integrity. The charge alteration introduced by this mutation promotes aberrant protein-protein interactions and accelerates tau aggregation into neurofibrillary tangles, a hallmark pathological feature. The variant affects a protein with critical molecular functions including actin binding, apolipoprotein binding, and DNA binding, while disrupting biological processes such as axon development and triggering astrocyte activation. The mutation's impact on tau's interaction network—particularly with heat shock proteins (HSP90AB1), kinases (GSK3B), and synuclein (SNCA)—suggests widespread downstream effects on neuronal homeostasis and synaptic function.

## Clinical Significance

The N279K mutation is clinically classified as pathogenic and serves as a causative variant for frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), not classical Alzheimer's disease. Carriers typically present with symptom onset in their 40s-50s, experiencing rapid cognitive decline accompanied by movement disorders characteristic of the frontotemporal dementia spectrum. The mutation's location in the microtubule-binding domain provides a mechanistic explanation for the accelerated disease progression observed in affected individuals. Diagnostic methods have been developed to distinguish N279K-associated tauopathy from other tau variants, establishing specific biomarker patterns crucial for clinical diagnosis and family counseling. The baseline clinical data collection for this variant is essential for understanding disease trajectories and developing personalized treatment approaches.

## Therapeutic Landscape

Therapeutic development for TAU N279K benefits from identification of aggregation hotspots within the tau protein, particularly residues 542-546 (aggregation score: 0.60). The candidate peptide CP-TAU-001 has been computationally designed to target this high-risk aggregation region, providing a rational approach to inhibiting pathological tau assembly. The targeting rationale focuses on blocking β-sheet formation in regions prone to forming the core of neurofibrillary tangles. While specific peptide inhibitors with published efficacy data were not detailed in the current findings, the therapeutic landscape shows promise through structure-guided design approaches leveraging AlphaFold structural predictions (9 structures available). The identified aggregation hotspot represents an actionable target for small molecule or peptide-based interventions aimed at preventing tau polymerization.

## Research Directions

Critical knowledge gaps remain regarding the N279K variant's specific effects on tau post-translational modifications and how the mutation influences tau's interactions with its known binding partners under pathological conditions. Future research should prioritize: (1) validating CP-TAU-001 efficacy in cellular and animal models carrying the N279K mutation; (2) elucidating structural changes induced by the mutation using cryo-EM or advanced NMR techniques; (3) investigating whether the mutation creates unique therapeutic vulnerabilities through synthetic lethality approaches; and (4) establishing natural history studies to better define progression biomarkers specific to N279K carriers. Integration of patient-derived iPSC models could provide crucial insights into early pathogenic events and enable high-throughput screening for variant-specific therapeutics.

---

## Agent Findings

### Literature (1)
- **2026-05-12:** These papers provide direct insights into tau N279K pathology through diagnostic assays and reveal broader mechanisms of tau-mediated neurodegeneration relevant to this variant. The findings on tau kinase inhibition and synaptic dysfunction offer potential therapeutic approaches for tau variants like N279K.

### Clinical (1)
- **2026-05-12:** The N279K mutation in the TAU protein represents the initial data collection point for studying a pathogenic variant that causes frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), not Alzheimer's disease specifically. This baseline measurement is clinically significant because the N279K substitution occurs in the microtubule-binding domain of tau, reducing its ability to bind and stabilize microtubules while increasing tau aggregation into neurofibrillary tangles. Establishing baseline data for this variant is essential for tracking disease progression and developing targeted therapies, as carriers typically develop symptoms in their 40s-50s with rapid cognitive decline and movement disorders.

### Structural (1)
- **2026-05-13:** AlphaFold structure update: Baseline check: 9 structure(s) found

### Synthesis (1)
- **2026-05-13:** Synthesis of 1 findings (peptides): The TAU N279K variant associated with Alzheimer's disease shows promising therapeutic potential base...

---

*Generated by [Clarity Protocol](https://clarityprotocol.io)*

**Data Sources:**
- Structure predictions: AlphaFold via ColabFold
- Clinical variant data: ClinVar, gnomAD
- Disease associations: Open Targets Platform
- Research findings: AI agents (PubMed, clinical databases)